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Background: Metabolic predictors and the atherogenicity of oxidized LDL (oxLDL) and the speciﬁc antibodies
against oxLDL (oxLDL Ab) are unclear and controversial.
Methods: In 107 adults without atherosclerotic manifestations, we measured oxLDL and oxLDL Ab, and also
the activities of CETP, PLTP, lipases and the carotid intima-media thickness (cIMT). Comparisons were per-
formed for the studied parameters between the lowest and the highest tertile of oxLDL and oxLDL Ab, and
the relationships between studied variables were evaluated.
Results: Subjects with higher oxLDL Ab present reduced hepatic lipase activity and borderline increased cIMT.
In the highest oxLDL tertile, besides the higher levels of total cholesterol, LDL-C and apoB100, we found re-
duced CETP activity and higher cIMT. A signiﬁcant correlation between oxLDL Ab and cIMT, independent of
oxLDL, and a borderline correlation between oxLDL and cIMT independent of oxLDL Ab were found. In the
multivariate analysis, apoAI was a signiﬁcant predictor of oxLDL Ab, in contrast to regulation of oxLDL by
apoB100, PLTP and inverse of CETP.
Conclusions: In adults without atherosclerotic disease, the metabolic regulation and carotid atherosclerosis of
oxLDL Ab and oxLDL groups, characterized a dual trait in oxLDL Ab, as a contributor to carotid atherosclerosis,
much less so than oxidized LDL, and with a modest atheroprotective role.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Epidemiological studies have established that an elevated plasma
level of low density lipoprotein (LDL) represents one of the most impor-
tant risk factors for the development of cardiovascular disease (CVD)
[1,2]. LDL is a hydrophilic complex of lipids and apolipoprotein B100
(apoB100), and constitutes one of the major lipid carriers in plasma. A
portion of circulating plasma LDL can enter the subendothelial space ofantibodies against oxLDL; IC,
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ia).
evier OA license.the vessels, where it undergoes chemical modiﬁcations, such as the oxi-
dation [3].
It has been suggested that LDL oxidationplays an important role in the
pathogenesis of atherosclerosis. Oxidized LDL (oxLDL) represents oxida-
tive modiﬁcations of both lipid and protein components of the LDL parti-
cle, and the consequent structural changes enhance LDL uptake by
macrophage through scavenger receptors. oxLDL is a positive chemotactic
factor for monocytes, which are differentiated into macrophages, leading
to lipid-laden foam cell formation and fatty streak development, one of
the earliest steps in the progression of the atherosclerotic plaque [3].
Also, oxLDL exerts cytotoxic effects on endothelial cells, increasing plate-
let activation, stimulating themigration and proliferation of smoothmus-
cle cells, thus initiating the atherosclerotic process [4].
Oxidativelymodiﬁed LDL is more immunogenic than the native form,
and induces the formation of immunogenic epitopes in the LDLmolecule,
which leads to the formation of speciﬁc antibodies against oxLDL (oxLDL
Ab) [5,6]. The existence of oxLDL Ab has been known for a long time, but
their clinical role is unclear [7].Whereas some studies have shown that, in
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development and CVD [8–10], other authors reported an inverse associa-
tion between atherosclerosis and the level of these antibodies [11,12],
showing that oxLDL Ab can block the uptake of oxLDL by macrophages
in atherosclerotic lesions [13].
A direct consequence of autoantibody synthesis against modiﬁed LDL
is the formation of immune complexes (IC) [14–16]. oxLDLs have the po-
tential to form ICwith their corresponding antibodies, and via Fc receptor
signaling and complement activation, they may modulate the inﬂamma-
tion in atherosclerosis [17]. These IC are detectable in both serumandath-
eromatous plaque, where both oxLDL and oxLDL Ab have been found
[18–20]. These IC are potentmacrophage activators [16,21] and consider-
ably more efﬁcient than oxLDL in induction of lipid accumulation [16],
and in promotion of human monocytic cell survival [22].
Previous studies have looked into the metabolic regulation of oxLDL
[23], but very few on oxLDL Ab [24]. Therefore, one aspect that should
be investigated is the metabolic regulation of these biomarkers, in
order to better understand the role of oxLDL Ab in the atherosclerotic
process as compared to oxLDL.
In the same scenario, other studies have investigated the relationship
of oxLDL [25–27] and oxLDL Ab to the carotid intima-media thickness
(cIMT) [25,28,29] but results were inconclusive. The measurement of
cIMT by ultrasonography is a non-invasive method to study coronary ar-
tery disease, widely used in practice as an inexpensive, reliable, and re-
producible method [30].
In this study, we aimed at investigating the metabolic predictors of
oxLDL Ab and of oxLDL, in order to understand their plasma variations,
and also their associations with carotid atherosclerosis through cIMT
measurements.
2. Materials and methods
2.1. Experimental protocol
The present cross-sectional study was conducted with 107 consecu-
tive adult individuals, from 19 to 78 years, 59% female (F) and 41% male
(M). All participants were recruited from the University of Campinas
Teaching Hospital, at the city of Campinas, São Paulo, Brazil and had pre-
viously volunteered as controls in another research protocol at the Uni-
versity Medical Center.
In a ﬁrst visit, blood samples were collected after a 12 h fast and a
medical physical examination was performed, including the collection
of anthropometric data. They answered a detailed oral questionnaire
aimed at determining the presence of cardiovascular diseases (presence
of angina pectoris, myocardial infarction, coronary insufﬁciency, the his-
tory of coronary revascularization procedures, coronary angioplasty and
coronary grafting bypass), presence of diabetes, cigarette smoking, posi-
tive family history of CVD, use of hormone replacement therapy or con-
traceptive pills and other related drugs, diabetes mellitus, body mass
index (BMI)>30 (kg/m2), liver and kidney diseases. The volunteers
were excluded if they fulﬁlled one of the characteristics above. Asymp-
tomatic normolipidemic volunteers (except 8% of all participants charac-
terized by total cholesterol up to 250 mg/dl and LDL-C up to 154 mg/dl)
were chosen after a preliminary laboratory selection and were invited
to participate in the study.
Food consumption was measured with the use of a standardized
questionnaire administered by a nutritionist. The selected participants
were invited to a second visit to have their cIMT determined by Doppler
ultrasound and always by the same expert radiologist. This studywas ap-
proved by the University of Campinas Medical School Ethics Committee
and all the participants signed an informed consent.
2.2. Biochemical measurements
Plasma glucose, urea, uric acid, alanine aminotransferase and
γ-glutamiltransferase were assayed in an automated system (RocheModular System) using enzymaticmethods fromRoche (RocheDiagnos-
tics, Mannheim, Germany). Thyroid stimulating hormone (TSH) was
measured by electrochemiluminescence, using a commercial kit in the
Elecsys (Roche).
2.3. Lipid, apolipoprotein and lipoprotein analyses
Venous blood was obtained after a 12 h fasting period, and serum
was separated and kept frozen at−80 °C. Total cholesterol and triglycer-
ides were determined using enzymatic methods and reagents provided
by Roche Diagnostics (Mannheim, Germany) in an automated system.
Phospholipids (PL) were measured by enzymatic colorimetric assays
(Wako Chemicals, Richmond, VA). High-density lipoprotein cholesterol
(HDL-C) was measured using a direct method (3rd generation) [31]
in an automated system (Roche Diagnostics, Mannheim, Germany).
LDL-C was estimated by the Friedewald's formula. Apolipoproteins A–I
(apoA-I), B100 and lipoprotein (a) were measured by nephelometric
assays in the Dade Boehringer System (Boehringer, Germany).
2.4. Detection of antibodies to oxidized LDL
oxLDL Ab were measured in plasma by ELISA, as described by
Zaratin et al. [32]. Polystyrene microtiter plates (Costar, Cambridge,
MA)were coatedwith 1 μg/mL of human copper-oxidized LDL in car-
bonate/bicarbonate buffer, pH 9.4, and kept overnight at 4 °C. The
plates were blocked with a 50 g/L solution of fat-free milk (Molico/
Nestlé, SP, Brazil) in 0.01 mol/L PBS and incubated for 2 h at room
temperature. After washing with PBS, the plasma samples were
added, diluted 1:200 in PBS (v/v), and incubated for 18 h. The plates
were, then, washed four times with PBS containing 0.2 mL/L Tween
20 (PBS-T), and incubated with a peroxidase conjugated rabbit
anti-human immunoglobulin G antibody at room temperature for
1 h with a subsequent wash. Finally, substrate solution (5 g/L of
tetramethylbenzidine in DMSO, 300 g/L H2O2, citrate buffer, pH
5.5) was added and, after incubation at room temperature for
15 min, the reaction was stopped by adding 2.0 M sulfuric acid.
The optical density (OD) was then measured in a microplate read-
er (Titertek Multiskan MCC/340P, model 2.20, Labsystems, Finland) at
450 nm. The results are presented as the OD readings (arbitrary
units) relative to the ranking values (% of OD) in the groups. The
inter assay CV was 5–13%.
2.5. Detection of oxidized LDL
The concentration of oxLDL in plasma was measured using the
“Oxidized LDL ELISA” kit (catalogue number 10-1143-01, Mercodia
AB, Uppsala, Sweden). This is a sandwich enzyme-linked immunosor-
bent assay procedure that uses the murine monoclonal antibody
mAb-4E6 as capture antibody and a peroxidase-conjugated anti-
apoB100 antibody that recognizes oxLDL bound to the solid phase.
Intra and inter-assay coefﬁcients of variation were 5–6% respectively
(accord to the manufactory). To estimate the extent of LDL oxidation
and the oxLDL particle number, the ratios of oxLDL to LDL-C and of
oxLDL to apoB100 were calculated. These estimates were expressed
as U oxLDL/mmol LDL-C and U oxLDL/g apoB100, respectively [23].
2.6. Determination of lipases and transfer proteins
Cholesteryl ester transfer protein (CETP), phospholipid transfer pro-
tein (PLTP), lipoprotein lipase (LPL) and hepatic lipase (HL) activities
were determined by radiometric methods as shown below.
Heparin (Liquemine®, Roche) was injected intravenously (100 UI/kg
of body weight) as described for measurements of lipoprotein lipase
and hepatic lipase [33], and blood samples drawn 15min later. The plas-
mawas isolated by centrifugation at 4 °C, 1000×g for 10 min. LPL and HL
activities were measured in the post-heparin plasma samples, on the
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substrate and NaCl (1 M) as the LPL inhibitor. The results are expressed
as nmol FFA/mL/h [33].
CETP was analyzed by an exogenous assay that measures the
transfer of radiolabeled cholesteryl ester (CE) between a normal
donor pool of 14CE-HDL and an unlabeled acceptor mixture of very-
low density lipoprotein (VLDL) plus LDL having the plasma as CETP
source [34]. The results are expressed as percent of cholesteryl ester
transferred from HDL to VLDL plus LDL in 4 h.
The activity of PLTP was measured by an exogenous radiometric
method using phospholipid liposomes as the substrate and an HDL
pool, obtained from healthy plasma donors, as the acceptor [35].
The activity is expressed as the rate of phospholipid transferred to
HDL/h. The assays for CETP, PLTP and lipases were carried out in trip-
licates. The inter-assay CVs were 12%, 2%, 9% and 8%, respectively, for
CETP, PLTP, LPL and HL.
2.7. Carotid ultrasound
High resolution B-mode carotid ultrasonography was performed by a
single trained sonographer, whowas blind to the subject's identity, using
a 6–9MHz linear array ultrasound imaging system (ATL HDI 1500 and
3500 Ultrasound System, Advanced Technology Laboratories Ultrasound,
Bothell, EUA). Longitudinal measurements weremade of segments of the
common carotid arteries at the distal wall and at 1 cm from the bifurca-
tion, according to a standardizedmethod [36]. Themean cIMTwas calcu-
lated as the average of ﬁve measurements on each side (right and left)
and expressed in mm. Maximum cIMT (max cIMT) was deﬁned as the
maximum thickness of the intima-media complex, including plaques.
2.8. Other measurements
BMI (kg/m2) was calculated by weight in kilograms divided by the
square of height in meters. Waist circumference (WC) was measured
with a ﬂexible tape, in the midpoint between the lowest rib and the
iliac crest, according to the World Health Organization Guidelines.
2.9. Statistical analysis
Data were analyzed using both SPSS and SAS statistical software. Log-
arithmic transformation was performed on individual values of skewed
variables, if not otherwise stated. Differences in continuous and categori-
cal variables were determined using Mann–Whitney, Kruskal–Wallis,
Dunn, Tukey aswell as ANCOVA and aχ2 test respectively. The Spearman
test was used to correlate the variables in the groups and adjustments
were made when needed.
Univariate regression analyses were also performed. A hierarchical
multiple stepwise linear regression analysis was performed in all studied
population to assess the inﬂuence of metabolic independent parameters
on the dependent variables oxLDL Ab, oxLDL, oxLDL/apoB100 and
oxLDL/LDL-C. The results were expressed as coefﬁcients of determination
(R2) that represent the percent of variation in the dependent variables
explained by the independent variables. Sequentially, the same depen-
dent variables were tested for the inﬂuences of the same independent
variables in two sub-population samples: in the higher tertiles of oxLDL
Ab and of oxLDL. Differences and correlations at p-values≤0.05 were
considered statistically signiﬁcant and between 0.05 and 0.10 were con-
sidered marginally signiﬁcant.
3. Results
3.1. Clinical characteristics of the studied population
Table 1 summarizes the clinical characteristics of all the partici-
pants and by tertiles of oxLDL Ab and oxLDL. The population was clas-
siﬁed by tertiles deﬁned by oxLDL Ab or oxLDL: lower (L) oxLDL Ab(≤0.23 OD, n=34), intermediate (I) tertile (0.24–0.35 OD, n=34)
and highest tertile (H) (≥0.36 OD, n=34); and lower oxLDL tertile
(≤46.2 U/L, n=35), intermediate oxLDL tertile (46.3–69.9 U/L,
n=36) and highest tertile (≥70.0 U/L, n=36). There was an overlap
of individuals who belonged to the same tertile groups: in lower
(22%); in intermediate (11%) and in higher (16%) groups.
Age and BMI increased, aswell as gender (female) andWCmarginally
with increasing oxLDL Ab tertiles. In contrast, all the clinical parameters
(Table 1) were higher, such as age, gender (female), BMI, WC and blood
pressure with increasing oxLDL tertiles. The anthropometric differences
of age, gender, BMI and systolic blood pressure (SBP) among the groups
were corrected in the following comparisons by ANCOVA.
Table 2 displays the biochemical parameters studied.
The only biochemical parameter that tended to decrease by oxLDL Ab
tertileswas triglycerides/HDL-C, an estimative of LDLparticle size [37] but
in oxLDL, LDL-C, apoB100, and the Cholesterol/HDL-C (Castelli I index)
[38] were increased by tertiles (Table 2). Fasting post-heparin plasma
LPL did not vary with tertiles for both markers (Table 2), and HL activity
decreased signiﬁcantly by oxLDL Ab tertile. In higher oxLDL, CETP activity
decreased signiﬁcantly, but PLTP activity did not change in either group.
Glucose did not change with tertile distribution.
3.2. Antibodies against oxLDL titers, oxLDL and LDL oxidative markers
and its correlations
In Table 3 the variations of antibodies and LDL oxidativemarkers in in-
creasing titers of oxLDL Ab and of oxLDL are shown.With increasing titers
of oxLDLAb, oxLDL/apoB100 (U/g) presented a borderline increase. oxLDL
did not change. With oxLDL increasing concentrations oxLDL/apoB100
(U/g) and oxLDL/LDL (U/mmol) also increased, but not oxLDL Ab.
3.3. Relationships between variables
The correlations between oxLDL Ab, oxLDL and oxLDL/apoB100 and
oxLDL/LDL-C ratios with biochemical parameters, lipases and transfer
proteins are displayed in Table 4.We alsomade the Spearman correlation
test between cIMT and oxLDL Ab adjusting for oxLDL in addition to other
variables used above and oxLDL with cIMT adjusting for oxLDL Ab and
we observed signiﬁcant and borderline correlations (p=0.041 and
p=0.059, respectively).
3.4. Multivariate analysis
In order to evaluate if some of the observed relationships in the uni-
variate analyses are independent of each other, metabolic and anthropo-
metric effects of several variables were studied and several models of
multiple linear regression analysis were proposed, where oxLDL Ab,
oxLDL, oxLDL/apoB100 and oxLDL/LDL-C were addressed as dependent
variables and age, sex, BMI, WC, SBP, diastolic blood pressure (DBP), cho-
lesterol, triglycerides, LDL-C, HDL-C, apoA-I, apoB100, LH, LPL, CETP, and
PLTP, as independent variables (Table 5).
oxLDL Ab were associated negatively with PLTP (R2=12.44,
p≤0.044) in the univariate analysis. The multivariate analysis indicated
that in all population sample oxLDL Ab (Table 5) was independently de-
termined only by apoAI; on the contrary oxLDL was determined mainly
by apoB100, CETP (inverse) and PLTP. In the linear regression models
controlled for sex, age, BMI, SBP and HDL-C neither oxLDL/lDL-C nor
oxLDL/apoB100 ratios were associated with the selected variables. LPL
and HL failed to explain all four dependent variables. LDL-C in all popula-
tion showed a strong regulation by apoB100 (R2 partial=0.4583 and
pb0.001). Sequentially, the same dependent variables in the regression
analysis model shown above were tested only in the highest tertiles of
oxLDL Ab and oxLDL. BMI most strongly determined oxLDL (R2
partial=0.6311, p≤0.006); no variables appeared to control oxLDL Ab
in the highest tertile.
Table 1
Clinical characteristics of the studied population separated in all the population and by tertiles (lower, intermediate and higher).
Variables All
(n=102 or 107)
oxLDL Ab oxLDL
L
(≤0.23 OD)
(n=34)
I
(0.24–0.35 OD)
(n=34)
H
(≥0.36 OD)
(n=34)
p-Values L
(≤46.2 U/L)
(n=35)
I
(46.3–70 U/L)
(n=36)
H
(≥70.1 U/L)
(n=36)
p-Values
Age (years) 42±16 34±13a 39±14a 52±15b ≤0.001 29±9a 46±16b 50±13a,b ≤0.001
Gender (F/M) 71/36 19/15a 21/13a,b 28/06b 0.052 20/15a,b 21/15a 30/6b 0.030
BMI (kg/m2) 25±5 23±2a 25±4a,b 26±5b 0.014 22±3a 25±4b 26±4b ≤0.001
WC (cm) 80±10 77±9a 79±12a,b 83±11b 0.068 74±8a 82±13b 83±10a,b 0.001
SBP (mm Hg) 123±15 118±9 125±17 127±16 NS 115±11a 130±18b 124±13a,b ≤0.001
DBP (mm Hg) 80±10 77±7 81±12 81±8 NS 75±9a 83±10b 81±9a,b 0.005
Values expressed bymeans±SD. oxLDL Ab: auto-antibodies against oxidized low density lipoprotein. oxLDL: oxidized low density lipoprotein. L: lower tertile. I: intermediate tertile. H: higher
tertile. BMI: bodymass index.WC: waist circumference. SBP: systolic blood pressure. DBP: diastolic blood pressure. Mann–Whitney, X2-square and Kruskal–Wallis tests were used. a,b,cGroups
with the same letter are not signiﬁcantly different. p≤0.05: signiﬁcant differences and 0.05bp>0.10, borderline differences.
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intima-media thickness and variables
We measured the consequences of increasing levels of oxLDL Ab
and oxLDL on cIMT and maximal cIMT, as shown in Table 6.
cIMT increases marginally with increased oxLDL Ab tertiles by
38%, but with oxLDL tertiles a signiﬁcant increase of 51% was ob-
served between the ﬁrst and third tertiles. The maximal cIMT values
(mm) in both oxLDL and oxLDL Ab tertiles were the same: 0.76 in
the lower tertile, 1.27 in the intermediate tertile and 1.24 in the
higher tertile; also, no carotid plaques were observed.
The scatter plots shown in Fig. 1 present the relationships of cIMT
with oxLDL Ab, oxLDL and discriminators of oxidation and LDL parti-
cle number. In Fig. 1(a–d), oxLDL Ab, oxLDL, oxLDL/apoB100 and
oxLDL/lDL-C ratios were signiﬁcantly and positively associated after
adjustment for anthropometric variables. There was great similarity
among these associations, suggesting the presence of immune com-
plexes in the carotid wall. LDL-C was not associated with cIMT in
the studied population (data not shown).
4. Discussion
In this study, we investigated the relationships of carotid athero-
sclerosis with circulating oxLDL concentrations and particle number,
and oxLDL Ab titers. We went forward and investigated whichTable 2
Lipid, lipoprotein, apolipoprotein, lipase and transfer protein activities of antibodies against oxidize
Variables All
(n=107)
oxLDL Ab
L
(≤0.23 OD)
(n=34)
I
(0.24–0.35 OD)
(n=34)
H
(≥0.36 O
(n=34)
C (mg/dL) 198±56 180±56 199±63 217±4
TG (mg/dL) 87±43 85±45 95±53 82±2
LDL-C (mg/dL) 116±38 106±33 115±45 127±3
VLDL-C (mg/dL) 17±8.6 17±9 19±10 16±5
HDL-C (mg/dL) 66±24 58±30 65±19 74±1
PL (mg/dL) 216±50 219±51 209±46 219±5
apoAI (mg/dL) 164±37 147±27 165±36 183±3
apoB100 (mg/dL) 93±31 85±26 94±36 100±2
C/HDL-C 3.1±0.7 3.0±0.8 3.0±0.7 2.7±0
TG/HDL-C 1.4±0.8 1.4±1.0 1.2±0.8 1.1±0
HL (nmol FFA/mL/h) 2137±1383 2801±1357a 1805±1252a, b 1672±1
LPL (nmol FFA/mL/h) 2530±1257 2203±954 2695±1238 2751±1
CETP (% of transfer) 14±7.8 16±7 13±7 13±8
PLTP (% of transfer) 15±10 12.8±10 13.4±9 19.2±1
Glucose (mg/dL) 83±8 84±9 85±9 81±6
Values expressed by means±SD. oxLDL Ab: auto-antibodies against oxidized low density
tertile. H: higher tertile, oxLDL Ab in left panel, oxLDL in right panel. C: cholesterol. TG:
HDL-C: high-density lipoprotein. PL: phospholipids. apoAI: apolipoprotein AI. apoB100: ap
lipase. LPL: lipoprotein lipase. CETP: cholesteryl ester transfer protein. PLTP: phospholip
used, p-values adjusted for age, gender (women), BMI and SBP by ANCOVA. p≤0.05: a,b
and 0.05bp>0.10: borderline differences.metabolic factors could control these parameters in adults without
established atherosclerotic disease.
LDL oxidation has been identiﬁed as a key element in the develop-
ment of the atherosclerotic injury [39], acting as a pro-inﬂammatory
agent by inducing auto-antibodies and endothelial dysfunction [40].
It has been shown that oxLDL Ab may play important roles in athero-
sclerosis, and can be found in human plasma, as well as in human ath-
erosclerotic lesions [6]. Therefore, investigating this issue is central in
understanding their contributions to the atherosclerotic lesion.
Atherosclerosis is a progressive disease and asymptomatic indi-
viduals can reveal the basic mechanisms involved in the formation
of the lesions. In our study, the characterization of the degree of
oxidation and the immunological response to it were observed by
the reduced LDL size (triglycerides/HDL-C) [37], a higher number of
oxLDL particles and by the marginal oxLDL/apoB100 increase along
with oxLDL Ab tertiles, suggesting an enhanced antibody response
to oxidized LDL.
Also, we found oxLDL to correlate strongly with LDL-C and
apoB100. Shoji et al. [24], in a study with 130 healthy Japanese sub-
jects, described a positive correlation between oxLDL and LDL-C,
which they consider likely due to substrate availability for LDL oxida-
tion. However, they also found an inverse correlation between oxLDL
and oxLDL Ab, as opposed to the previously believed concept that
oxLDL Ab mirrored the amount of the oxLDL antigens in vivo [25].
In the present study, we did not ﬁnd any correlations betweend LDL and oxidized LDL in all the population and by tertiles (lower, intermediate and higher).
oxLDL
D)
p-Values L
(≤46.2 U/L)
(n=35)
I
(46.3–70 U/L)
(n=36)
H
(≥70.1 U/L)
(n=36)
p-Values
3 NS 155±47a 204±41a, b 233±49b ≤0.001
7 NS 71±38 89±42 100±43 NS
4 NS 85±21a 118±29b 142±38c ≤0.001
NS 14±7 17±8 20±8 NS
6 NS 57±30 69±19 70±17 NS
5 NS 195±49 217±36 239±55 NS
9 NS 141±33 172±31 177±37 NS
8 NS 68±17a 97±25b 113±28c ≤0.001
.7 NS 2.7±0.7a 3.0±0.6a, b 3.3±0.8b 0.013
.6 0.086 1.0±0.7 1.2±0.8 1.2±0.8 NS
044b 0.039 2552±1372 2061±1270 1792±1442 NS
500 NS 2442±876 2660±1280 2479±1557 NS
NS 17.3±7.0a 11.6±6.6a 13.0±8.5a,b 0.029
1 NS 11±7 14.7±11 20±10 NS
NS 83±8 85±9 83±8 NS
lipoprotein. oxLDL: oxidized low density lipoprotein. L: lower tertile. I: intermediate
triglycerides. LDL-C: low density lipoprotein. VLDL-C: very-low density lipoprotein.
olipoprotein B. C/HDL-C: Castelli I index. TG/HDL-C: LDL size estimation. HL: hepatic
id transfer protein. Mann–Whitney, Kruskal–Wallis, and Tukey–Kramer tests were
,cGroups with the same letter are not signiﬁcantly different; signiﬁcant differences
Table 3
Antibodies against oxidized LDL, oxidized LDL, oxLDL/apoB100 and oxLDL/LDL-C ratios of all the population and by tertiles (lower, intermediate and higher).
Variables All
(n=107)
oxLDL Ab oxLDL
L
(≤0.23 OD)
(n=34)
I
(0.24–0.35 OD)
(n=34)
H
(≥0.36 OD)
(n=34)
p-Values L
(≤46.2 U/L)
(n=35)
I
(46.3–70 U/L)
(n=36)
H
(≥70.1 U/L)
(n=36)
p-Values
oxLDL Ab (OD) 0.32±0.16 0.16±0.04 0.28±0.03 0.51±0.12 – 0.25±0.13 0.34±0.15 0.37±0.18 NS
oxLDL (U/L) 62.9±28.1 49±20 64±30 69±21 NS 35±8.21 58±6.72 95±20.50 –
oxLDL/apoB100 (U/g) 6.83±2.66 5.83±1.53 6.80±1.85 6.95±2.40 0.076 5.30±1.34 6.27±1.41 8.85±3.28 ≤0.001
oxLDL/LDL-C (U/mmol) 21.14±7.80 18.19±4.76 21.46±6.36 21.94±6.92 NS 16.32±4.47 19.74±4.01 27.23±9.23 ≤0.001
Values expressed bymeans±SD. oxLDL Ab: auto-antibodies against oxidized low density lipoprotein. oxLDL: oxidized low density lipoprotein. L: lower tertile. I: intermediate tertile. H: higher
tertile, oxLDLAb in left panel and oxLDL in right panel. oxLDL/apoB100 andoxLDL/LDL-C: LDL oxidation degree.Mann–Whitney, Kruskal–Wallis, and Tukey–Kramer testswere usedwere used;
p-values adjusted for age, gender (women), BMI and SBP by ANCOVA. p≤0.05: signiﬁcant differences and 0.05bp>0.10: borderline differences.
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subjects, where they found that plasma oxLDL had no linear correla-
tion with oxLDL antibodies [41]. This discrepancy could indicate the
complexity of the system, and raises a possibility that the pathophys-
iological roles of oxLDL Ab may vary depending on the stage of ath-
erosclerosis development.
Searching for the average variation of cIMT, in this study, between
the ﬁrst versus third tertile of oxLDL Ab or oxLDL, we observed in-
creases in 0.22 and 0.29 mm, respectively. These variations could ac-
count for increased risk of myocardial infarction, as described earlier:
for each increase of 0.03 mm in cIMT, the relative risk for nonfatal
myocardial infarction or coronary death is about 2.2% [42]. Although
the risk was higher with increasing oxLDL, the maximal cIMT value
was the same in the 3 tertiles of both marker groups. The fact that
both oxLDL and oxLDL Ab correlated with cIMT very similarly could
indicate the formation of ICs at the artery wall [17,18].
Because plasma oxLDL correlated positively and strongly with
LDL-C, we examined whether this was an independent association
and which variables could predict oxLDL, oxLDL particle number,
oxLDL Ab and LDL-C, using a linear multiple regression analysis. In
contrast to LDL-C, explained physiologically and mainly by apoB100,
oxLDL determinants were apoB100, CETP (inverse, as in the bivariate
correlation) and PLTP.
CETP is a plasma lipid transfer protein that has the ability to trans-
fer CE ester from HDL toward apoB containing lipoproteins, playing
an important role in the reverse cholesterol transport [43]. CETP ac-
tivity was lower in the highest oxLDL tertile (~24%) and presented
an inverse relationship with LDL oxidation, as described by Castilho
et al. [44], which could be explained by the transfer of oxidized lipids
from apoB100 containing lipoproteins to HDL mediated by CETP, that
acts as an anti-atherogenic protein.
Moreover, oxLDLwas positively regulatedbyPLTP, an importantmod-
ulator of lipoprotein metabolism, including inter-particle phospholipidTable 4
Signiﬁcant Spearman correlation coefﬁcients of antibodies against oxidized LDL, oxi-
dized LDL, oxLDL/apoB100 and oxLDL/LDL-C ratios with biochemical variables, lipases
and transfer proteins of the studied population.
Parameters Variables r p-Values
oxLDL
(n=107)
Cholesterol (mg/dL) 0.409 ≤0.001
LDL-C (mg/dL) 0.546 ≤0.001
apoB100 (mg/dL) 0.519 ≤0.001
Cholesterol/HDL-C 0.429 ≤0.001
CETP (% of transfer) −0.210 0.039
oxLDL/apoB100
(n=107)
oxLDL (U/L) 0.703 ≤0.001
oxLDL/LDL-C
(n=107)
oxLDL (U/L) 0.706 ≤0.001
PLTP (% of transfer) 0.219 0.036
LDL-C: low density lipoprotein cholesterol. apoB100: apolipoprotein B100. C/HDL-C:
Castelli I index. CETP: cholesteryl ester transfer protein. oxLDL: oxidized low density lipo-
protein. PLTP: phospholipid transfer protein. p-Values adjusted for age, gender, BMI and
SBP by ANCOVA; p≤0.05: signiﬁcant differences.transfer, remodeling of HDL, cholesterol and PL efﬂux from arterial intima
and the production of hepatic very low density lipoprotein. PLTP also
plays an important role in inﬂammation and oxidative stress [45]. The
consequences of the positive modulation by PLTP are described in the
model of overexpression of PLTP in mice, where the decrease of vitamin
E content in LDL is parallel to its increased oxidation [46].
On the other hand, oxLDL Ab were associated negatively with
PLTP, which could be considered an anti-atherogenic relationship,
and a beneﬁcial trait seen in the univariate analysis. In the multivari-
ate approach, the regulation of oxLDL Ab was simpler and explained
positively by the antiatherogenic apoA-I. ApoA-I is a predominant
component in HDL, that has been related to lecithin-cholesterol
acyltransferase activation [47] and HL inhibition [48] and increases
reverse cholesterol transport, suggesting that other regulators can
be indirectly involved in the lesion development.
Accordingly, HL activity was signiﬁcantly reduced (~40%) in the
highest oxLDL Ab tertile group. In HL deﬁciency, HDL particles are
enriched in triglycerides [49] and, therefore, not as good substrates
for CETP, which could lead to lower antioxidant capacity, and the gen-
eration of more oxLDL particles.
These ﬁndings indicate that oxLDL was regulated by apoB100,
CETP and PLTP, but oxLDL Ab only by apoA-I. The oxLDL/lDL-C and
oxLDL/apoB100 ratios have a similar behavior on cIMT as oxLDL Ab
and oxLDL, but the size was independent of the metabolic regulators
in the models.
To our knowledge, this is the ﬁrst study in adults without established
atherosclerotic disease that explored the main reverse cholesterol trans-
port proteins as determinants of oxLDL and oxLDL Ab and characterized
oxLDL Ab as a contributor to carotid atherosclerosis, much less so than
oxLDL and with a modest atheroprotective role. This study encourages
further investigations to elucidate the mechanisms involved in theTable 5
Multiple linear regression analysis for antibodies against oxidized LDL, oxidized LDL,
oxLDL/apoB100 and oxLDL/LDL-C ratios of the studied population.
Dependent variables Selected
variables
Β (SE) p-
Values
R2
partial
oxLDL Ab (n=90) apoAI 0.002 (0.001) 0.047 0.0398
oxLDL (n=92) apoB100a 0.781 (0.114) ≤0.001 0.2349
CETPa −0.129
(0.051)
0.014 0.0199
PLTPa 0.095 (0.046) 0.043 0.0178
oxLDL/apoB100
(n=92)
– – – –
oxLDL/LDL-C (n=92) – – – –
LDL-C (n=92) apoB100 0.861 (0.049) b0.001 0.4563
a Variables transformed into logarithms due to the absence of normal distribution. β
(SE): slope and standard error. R2: coefﬁcients of determination. Multivariate analysis:
controlled for age, gender, BMI, SBP and HDL-C. Linear regression ﬁtting using stepwise
method for variable selection: sex, age, BMI, WC, SBP, DBP, C, TG, LDL-C, HDL-C, apoAI,
apoB100, LH, LPL, CETP, and PLTP.
Table 6
Common carotid thickness of the studied population separated by tertiles of antibodies against oxidized and oxidized LDL (lower, intermediate and higher).
Variables All
(n=77)
oxLDL Ab oxLDL
L
(≤0.23 OD)
(n=29)
I
(0.24–0.35 OD)
(n=23)
H
(≥0.36 OD)
(n=21)
p-Values L
(≤46.2 U/L)
(n=33)
I
(46.3–70 U/L)
(n=25)
H
(≥70.1 U/L)
(n=19)
p-Values
Mean cIMT (mm) 0.69±0.21 0.58±0.06 0.72±0.28 0.80±0.18 0.068 0.57±0.05a 0.72±0.18b 0.86±0.29b 0.003
Max cIMT (mm) 1.27 0.76 1.27 1.24 – 0.76 1.27 1.24 –
Values expressed bymeans±SD. oxLDL Ab: auto-antibodies against oxidized low density lipoprotein. oxLDL: oxidized low density lipoprotein. L: lower tertile. I: intermediate tertile. H: higher
tertile, oxLDL Ab in left panel and oxLDL in right panel. Mean cIMT: carotid artery intima-media thickness median. Max cIMT:maximum carotid artery intima-media thickness value. Kruskal–
Wallis and Tukey–Kramer tests were used; p-values adjusted for age, gender, BMI and SBP by ANCOVA. p≤0.05: signiﬁcant differences and 0.05bp>0.10: borderline differences.
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sclerotic disease and in pathological states.
5. Conclusion
The relationships we found between oxLDL and the other studied
variables are clearly pro-atherogenic, except for the action of CETP trans-
ferring oxidized lipids from LDL to HDL, with atheroprotective action. The
LDL oxidation and particle number ratios presented signiﬁcant positive
associations with cIMT.
As for the oxLDL Ab, we found a diminished atherogenic role due to
theweaker response of cIMT as compared to oxLDL, and the lack of corre-
lationwith oxLDL and oxLDL/apoB100. However, the correlation of oxLDL
Ab with cIMT was similar to the other three biomarkers, suggestingFig. 1. a–d: Similar positive partial relationships of carotid intima-media thickness with antib
studied population. Correlations were evaluated by Spearman test. p-Values were adjustedthe formation of ICs at the artery wall site, and a predominantly non-
protective effect of oxLDL Ab on inﬂammatory carotid atherosclerosis.
Corroboratingwith this are the equally highmaximal cIMT values. There-
fore, these relationships characterize a dual trait for oxLDL Ab. With
higher apoA-I concentrations a positive modulation of antibodies is ob-
served but apoAI can reduce HL activity (as described in this study) and
increase LCAT, leading to HDL particles that have worse anti-oxidant ac-
tion, and inducing oxLDL Ab production.
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